Cardlytics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results and Issued Q2 Revenue Guidance With Its Midpoint Below Estimates. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $17 to $12.
Cardlytics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results and Issued Q2 Revenue Guidance With Its Midpoint Below Estimates. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $17 to $12.
Cardlytics公布的第一季度财务业绩喜忧参半，并发布了第二季度收入指引，其中点低于预期，此后，该公司股价走低。此外，尼德姆维持该股的买入评级，并将其目标股价从17美元下调至12美元。
Cardlytics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results and Issued Q2 Revenue Guidance With Its Midpoint Below Estimates. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $17 to $12.
Cardlytics公布的第一季度财务业绩喜忧参半，并发布了第二季度收入指引，其中点低于预期，此后，该公司股价走低。此外，尼德姆维持该股的买入评级，并将其目标股价从17美元下调至12美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。